How we work
Putting patients before profits
DNDi acts as a conductor of a ‘virtual orchestra’ of over 180 partners around the world to develop treatments for patients – not profits. By bringing together the public, private, academic, non-profit, and philanthropic sectors, we leverage the unique expertise of each partner to drive innovation for neglected populations.
Our not-for-profit R&D model follows six main principles
We ensure all of our work is rooted in the medical needs of the people we serve – from defining the characteristics needed for new treatments to discovering and developing new drugs and ensuring they are accessible and affordable.
We maintain DNDi’s scientific and financial independence in order to set priorities and make decisions according to the best science and the imperative of patients’ needs.
Collaborative, open & transparent
We are committed to sharing research data, knowledge, and costs – and we believe publicly or philanthropically funded R&D ought to be carried out in the public interest and shared as broadly and equitably as possible.
We foster R&D by facilitating scientific exchange, utilising and strengthening research capacity, and nourishing innovation networks – particularly in low- and middle-income countries.
We make sure the treatments we develop are affordable, available, and adapted to the communities who need them most.
We pilot and incubate new approaches to innovation, encourage public leadership, and engage as an informed advocate for a more effective and equitable biomedical R&D system.
A dynamic portfolio
In order to be able to respond to the constant evolution of public health needs, we have adopted a “dynamic portfolio” approach, which allows us to take on new disease areas with various operating models, while delivering on our objectives in diseases that we have worked on since our early days as a public interest R&D organization.
This approach, enshrined in the Business Plan 2015-23, is instrumental in that it allows us to pursue a variety of different intervention models. Thanks to the dynamic portfolio, DNDi has added mycetoma to its R&D portfolio, co-created and then incubated GARDP as an entity to accelerate R&D for drug-resistant infections, and more recently, embarked on a new project on cryptococcal meningitis.
We strive to hold ourselves to the highest standards of accountability, transparency, ethics, and best practice in all we do.
Become a partner
Help us bring the best science to the most neglected.
Get our latest news, personal stories, research articles, and job opportunities.